Werewolf Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table provides information regarding the fees billed by Ernst & Young LLP for the fiscal years ended December 31, 2025 and 2024:
| Fee Category | 2025 | 2024 |
|---|---|---|
| Audit fees(1) | $770,101 | $729,175 |
| Audit related fees | $— | $— |
| Tax fees(2) | $23,175 | $70,086 |
| All other fees(3) | $5,200 | $5,200 |
| Total fees | $798,476 | $804,461 |
(1) “Audit fees” during the 2025 and 2024 fiscal years consist of fees for the audit of our annual financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q and other professional services provided in connection with regulatory filings or engagements.
(2) “Tax fees” during the 2025 and 2024 fiscal years consist of fees for professional services, including tax compliance and advisory services primarily related to the preparation of state and federal tax returns.
(3) “All other fees” during the 2025 and 2024 fiscal years consist of subscription fees.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.